TY - JOUR
T1 - LCZ696 (sacubitril/valsartan) for patients with heart failure
AU - Hernandez, Adrian V.
AU - Pasupuleti, Vinay
AU - Banach, Maciej
AU - Bielecka-Dabrowa, Agata M.
N1 - Publisher Copyright:
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
PY - 2020/1/14
Y1 - 2020/1/14
N2 - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:. To assess benefits and harms of first-in-class angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (LCZ696) as compared to angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in chronic heart failure (HF) patients with either reduced, mid-range, or preserved ejection fraction.
AB - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:. To assess benefits and harms of first-in-class angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (LCZ696) as compared to angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in chronic heart failure (HF) patients with either reduced, mid-range, or preserved ejection fraction.
UR - https://www.scopus.com/pages/publications/85088244906
U2 - 10.1002/14651858.CD013517
DO - 10.1002/14651858.CD013517
M3 - Artículo
AN - SCOPUS:85088244906
SN - 1465-1858
VL - 2020
JO - Cochrane Database of Systematic Reviews
JF - Cochrane Database of Systematic Reviews
IS - 1
M1 - CD013517
ER -